echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Competition intensifies, and a large number of drug makers begin to retreat

    Competition intensifies, and a large number of drug makers begin to retreat

    • Last Update: 2020-07-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    "Pharmaceutical Network Industry Dynamics" Recently, the Chongqing Municipal Drug Administration issued a notice to cancel the "Drug Business License" announcement, a proposed cancellation of the "Drug Business License" announcement, involving a total of four pharmaceutical companiesit is worth noting that, from the content of the announcement, these pharmaceutical companies to cancel the "drug business license" are active applications, the reason for the company is to terminate the operation of drugs or closein fact, for pharmaceutical companies to voluntarily cancel the "drug production license" or "drug business license", at present, is nothing newshould say that this is a very common phenomenon in the industry, and, many are enterprises to actively apply for cancellationit is understood that in the near future, there are many pharmaceutical companies, drug manufacturers to apply for the cancellation of the "drug production license" or "drug business license.", such as July 13, Shaanxi Provincial Drug Administration website published "on the cancellation of the Ganzhou Pharmaceutical Building Chain Co., Ltdand other enterprises drug business license announcement", according to the "Drug Business License Management Measures" relevant provisions, after the study decision, agreed to the Ganzhou Pharmaceutical Building Chain Co., Ltdand other six companies to cancel the "Drug Business License" applicationOn June 15,, Jiangxi Provincial Drug Administration issued a notice that it agreed to cancel Jiangxi AIA Pharmaceutical Co., China Pharmaceutical Company's "Drug Business License" (license number: AA7970065), while withdrawing the certificate number A-JX14-94N of the "Pharmaceutical Management Practice Certification Certificate."industry generally believethat that many provinces such an active cancellation of the "drug business license" phenomenon may be due to the change in the pharmaceutical industry policy environment in recent years, regardless of strict supervision, drug tender, medical insurance fees, or consistent evaluation, will prompt pharmaceutical companies and drug manufacturers to adjust their product structure to appropriate market demandin this context, pharmaceutical companies and pharmacies business is no longer good, whether pharmaceutical companies or drug dealers, are facing the problem of transformation and developmentonce can not adapt and adjust their own can not keep up with the requirements of policies and industries, can only sell enterprises, seek cooperation, or take the initiative to write off, completely quitbut in fact, China is a large manufacturing country, the current overall industry environment is large and complete, want to further develop will certainly go in the direction of high-precisionand with a series of policies to guide industrial upgrading, some enterprises are eliminated will be an inevitable eventthe future, in the belt procurement, health insurance catalog adjustment and other policies more continuous and in-depth implementation, as well as the relevant departments of downstream terminal and commercial paper management efforts to more stringent supervision, coupled with hospital repayments and other issues, there will be more pharmaceutical companies and drug dealers, feel the enormous pressure of transformation and upgrading based on this, it will become very common for pharmaceutical companies to cancel the Drug Business License or The Drug Business License at a later date for pharmaceutical companies and pharmacies, both to accelerate the transformation and adjust the development strategy once can not actively adapt and adjust can not keep up with the requirements of policies and industries, it can only face elimination
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.